CN101940738A - Coix seed anticancer Chinese medicament and preparation method thereof - Google Patents
Coix seed anticancer Chinese medicament and preparation method thereof Download PDFInfo
- Publication number
- CN101940738A CN101940738A CN 201010237432 CN201010237432A CN101940738A CN 101940738 A CN101940738 A CN 101940738A CN 201010237432 CN201010237432 CN 201010237432 CN 201010237432 A CN201010237432 A CN 201010237432A CN 101940738 A CN101940738 A CN 101940738A
- Authority
- CN
- China
- Prior art keywords
- glyceryl
- coix seed
- retention time
- molecular weight
- minutes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000077995 Coix lacryma jobi Species 0.000 title claims abstract description 45
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000007788 liquid Substances 0.000 claims abstract description 25
- 239000000126 substance Substances 0.000 claims abstract description 23
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- -1 Glyceryl Palmitate Dilinoleate Chemical compound 0.000 claims abstract description 8
- 239000002552 dosage form Substances 0.000 claims abstract description 6
- 238000002347 injection Methods 0.000 claims abstract description 6
- 239000007924 injection Substances 0.000 claims abstract description 6
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 claims abstract description 5
- 239000002253 acid Substances 0.000 claims abstract description 5
- QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000006189 buccal tablet Substances 0.000 claims abstract description 4
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 229940096898 glyceryl palmitate Drugs 0.000 claims abstract description 4
- 239000006187 pill Substances 0.000 claims abstract description 4
- 239000007921 spray Substances 0.000 claims abstract description 4
- 239000003826 tablet Substances 0.000 claims abstract description 4
- 229940046011 buccal tablet Drugs 0.000 claims abstract description 3
- 229940023488 pill Drugs 0.000 claims abstract description 3
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 claims abstract description 3
- 229940117972 triolein Drugs 0.000 claims abstract description 3
- 230000014759 maintenance of location Effects 0.000 claims description 20
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims description 7
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 6
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 4
- 235000020778 linoleic acid Nutrition 0.000 claims description 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 4
- 235000021314 Palmitic acid Nutrition 0.000 claims description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 3
- 239000012071 phase Substances 0.000 claims description 3
- HBOQXIRUPVQLKX-BBWANDEASA-N 1,2,3-trilinoleoylglycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)COC(=O)CCCCCCC\C=C/C\C=C/CCCCC HBOQXIRUPVQLKX-BBWANDEASA-N 0.000 claims description 2
- 241001397104 Dima Species 0.000 claims description 2
- RAFKCLFWELPONH-UHFFFAOYSA-N acetonitrile;dichloromethane Chemical group CC#N.ClCCl RAFKCLFWELPONH-UHFFFAOYSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- VJZWIFWPGRIJSN-XRHABHTOSA-N dilinoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O VJZWIFWPGRIJSN-XRHABHTOSA-N 0.000 claims description 2
- 238000000105 evaporative light scattering detection Methods 0.000 claims description 2
- HBOQXIRUPVQLKX-UHFFFAOYSA-N linoleic acid triglyceride Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC HBOQXIRUPVQLKX-UHFFFAOYSA-N 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims 1
- 238000000605 extraction Methods 0.000 abstract description 9
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 abstract description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 abstract description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 abstract description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 abstract description 2
- 239000005642 Oleic acid Substances 0.000 abstract description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 abstract description 2
- DRAWQKGUORNASA-UHFFFAOYSA-N (2-hydroxy-3-octadec-9-enoyloxypropyl) octadec-9-enoate Chemical compound CCCCCCCCC=CCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCC=CCCCCCCCC DRAWQKGUORNASA-UHFFFAOYSA-N 0.000 abstract 3
- GFAZGHREJPXDMH-UHFFFAOYSA-N 1,3-dipalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCC GFAZGHREJPXDMH-UHFFFAOYSA-N 0.000 abstract 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 abstract 2
- 229940049918 linoleate Drugs 0.000 abstract 2
- 125000005456 glyceride group Chemical group 0.000 abstract 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 abstract 1
- 229940090044 injection Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 19
- 239000000284 extract Substances 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 13
- 230000000259 anti-tumor effect Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 201000007270 liver cancer Diseases 0.000 description 12
- 208000014018 liver neoplasm Diseases 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 4
- XIRNKXNNONJFQO-UHFFFAOYSA-N ethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC XIRNKXNNONJFQO-UHFFFAOYSA-N 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- OALYTRUKMRCXNH-UHFFFAOYSA-N 5-pentyloxolan-2-one Chemical compound CCCCCC1CCC(=O)O1 OALYTRUKMRCXNH-UHFFFAOYSA-N 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 239000001149 (9Z,12Z)-octadeca-9,12-dienoate Substances 0.000 description 2
- WTTJVINHCBCLGX-UHFFFAOYSA-N (9trans,12cis)-methyl linoleate Natural products CCCCCC=CCC=CCCCCCCCC(=O)OC WTTJVINHCBCLGX-UHFFFAOYSA-N 0.000 description 2
- LNJCGNRKWOHFFV-UHFFFAOYSA-N 3-(2-hydroxyethylsulfanyl)propanenitrile Chemical compound OCCSCCC#N LNJCGNRKWOHFFV-UHFFFAOYSA-N 0.000 description 2
- 101150080924 CNE1 gene Proteins 0.000 description 2
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- PKIXXJPMNDDDOS-UHFFFAOYSA-N Methyl linoleate Natural products CCCCC=CCCC=CCCCCCCCC(=O)OC PKIXXJPMNDDDOS-UHFFFAOYSA-N 0.000 description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 235000000431 campesterol Nutrition 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 2
- 229940031016 ethyl linoleate Drugs 0.000 description 2
- 229940067592 ethyl palmitate Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- JARKCYVAAOWBJS-UHFFFAOYSA-N hexanal Chemical compound CCCCCC=O JARKCYVAAOWBJS-UHFFFAOYSA-N 0.000 description 2
- 230000003832 immune regulation Effects 0.000 description 2
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 150000002759 monoacylglycerols Chemical class 0.000 description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 2
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 2
- 235000012141 vanillin Nutrition 0.000 description 2
- WRIDQFICGBMAFQ-KHPPLWFESA-N (z)-octadec-8-enoic acid Chemical compound CCCCCCCCC\C=C/CCCCCCC(O)=O WRIDQFICGBMAFQ-KHPPLWFESA-N 0.000 description 1
- BDXJANJAHYKTMI-UHFFFAOYSA-N 2,3,4,5-tetramethyl-1h-pyrrole Chemical class CC=1NC(C)=C(C)C=1C BDXJANJAHYKTMI-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 2,3-Dihydroxypropyl oleate Natural products CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- DPQCZNIGGNJGTD-UHFFFAOYSA-N Chloride-(??)-2-Methylpentanoic acid Natural products CCCCCCC=CCCCCCCCCCC(=O)OC(C)C(C)OC(=O)CCCCCCCC=CCCCCCC DPQCZNIGGNJGTD-UHFFFAOYSA-N 0.000 description 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 1
- DPQCZNIGGNJGTD-MVCBGFDASA-N Coixenolide Chemical compound CCCCCC\C=C\CCCCCCCCCC(=O)O[C@@H](C)[C@@H](C)OC(=O)CCCCCCC\C=C/CCCCCC DPQCZNIGGNJGTD-MVCBGFDASA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 229920001284 acidic polysaccharide Polymers 0.000 description 1
- 150000004805 acidic polysaccharides Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- OALYTRUKMRCXNH-QMMMGPOBSA-N gamma-Nonalactone Natural products CCCCC[C@H]1CCC(=O)O1 OALYTRUKMRCXNH-QMMMGPOBSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- BMQNWLUEXNQIGL-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O.CCCCCCCCC(O)=O BMQNWLUEXNQIGL-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
一种薏苡仁抗癌中药,从薏苡仁中提取的具有抗癌作用的化学物质组分,所述具有抗癌作用的化学物质组分主要有:三亚油酸甘油酯、二亚油酸油酸甘油酯、棕榈酸二亚油酸甘油酯、亚油酸二油酸甘油酯、棕榈酸亚油酸油酸甘油酯、二棕榈酸亚油酸甘油酯、三油酸甘油酯、棕榈酸二油酸甘油酯、二棕榈酸油酸甘油酯、二油酸硬脂酸甘油酯。从薏苡仁中提取的有效化学物质组做成以下制剂或剂型:口服液、片剂、胶囊、含片、丸剂、注射剂或喷雾给药制剂,本发明的优点在于:提取工艺简单、能制成多种剂型,具有较好的抗癌作用。
A coix seed anticancer traditional Chinese medicine, the chemical substance components with anticancer effect extracted from coix seed, the chemical substance components with anticancer effect mainly include: trilinoleic acid glyceride, dilinoleic acid oleic acid Glycerides, Glyceryl Palmitate Dilinoleate, Glyceryl Linoleate Dioleate, Glyceryl Palmitate Linoleate, Glyceryl Dipalmitate Linoleate, Glyceryl Trioleate, Dioleate Palmitate Glyceryl Dioleate, Glyceryl Dioleate, Glyceryl Dioleate. The effective chemical substance group extracted from coix seed is made into the following preparations or dosage forms: oral liquid, tablet, capsule, buccal tablet, pill, injection or spray preparation. The advantages of the present invention are that the extraction process is simple and can be made into A variety of dosage forms, with good anticancer effect.
Description
发明领域field of invention
本发明涉及了一种具有抗肿瘤(抗癌)作用的中药,特别是从薏苡仁提取的化合物中制备具有抗肿瘤(抗癌)作用的有效化学物质组的方法。 The invention relates to a traditional Chinese medicine with an anti-tumor (anti-cancer) effect, in particular to a method for preparing an effective chemical substance group with an anti-tumor (anti-cancer) effect from a compound extracted from coix seed. the
背景技术Background technique
薏苡仁为禾本科植物薏苡(Coix lacryma-jobi L.var.ma-yuen(Roman.)Stapf)的干燥成熟种仁,呈宽卵形或长椭圆形,长4~8mm,宽3~6mm。表面乳白色,光滑,偶有残存的黄褐色种皮;一端钝圆,另端较宽而微凹,有1淡棕色点状种脐;背面圆凸,腹面有1条较宽而深的纵沟。质坚实,断面白色,粉性。我国大部分地区均产,主产于福建、河北、辽宁等地。 Coix seed is the dry mature seed kernel of Coix lacryma-jobi L.var.ma-yuen (Roman.) Stapf, a grass plant, which is broadly oval or oblong, 4-8mm long and 3-6mm wide. The surface is milky white, smooth, with occasional remnants of yellowish-brown testa; one end is blunt and round, the other end is wider and slightly concave, with a light brown dotted hilum; the back is round and convex, and the ventral side has a wide and deep longitudinal groove . The quality is solid, the section is white, powdery. It is produced in most parts of my country, mainly in Fujian, Hebei, Liaoning and other places. the
薏苡仁始载于《神农本草经》,其性甘味淡凉,具有利水渗湿、健脾止泻、除痹、排脓、解毒散结的功效。其中含薏苡仁酯(coixenolide),粗蛋白13%-14%,脂类2%-8%。脂类中三酰甘油61%-64%,二酰甘油6%-7%,一酰甘油4%,甾醇酯9%,游离脂肪酸17%-18%。在三酰甘油中亚油酸(linoleic acid)含量可达25%-28%,在游离脂肪酸中亚油酸含量为27%-28%,游离脂肪酸还有棕榈酸(palmitic acid),硬脂酸(stearic acid),顺-8-十八碳烯酸(cis-8-oc-tadecenoic acid)即油酸等。一酰甘油中有具抗肿瘤作用的α-单油酸甘油酯(α-monoolein),甾醇酯中有具促排卵作用的顺-、反-阿魏酰豆甾醇(cis-、trans-feruloylstigmasterol)和顺-、反-阿魏酰菜油甾醇(cis-、trans-feruloylcampesterol)等。还含抗补体作用的葡聚糖和酸性多糖CA-1、CA-2及降血糖作用的薏苡多糖(coixan)A、B、C。种子挥发油含69种成分,其中主要的有己醛(hexanal),己酸(hexanoic acid),2-乙基-3-羟基丁酸己酯(2-ethyl-3-hydroxy-hexylbutrate),γ-壬内酯(γ-nonalactone),壬酸(nonanoic acid),辛酸(octanoic aid),棕榈酸乙酯(ethylpalmitate),亚油酸甲酯(methyllinoleate),香草醛(vanillin)及亚油酸乙酯(ethyllinoleate)等。 Coix seed was first recorded in "Shen Nong's Materia Medica". It is sweet in nature and light in taste. It contains coixenolide,
在传统中医中药学研究中,均采用薏苡仁治疗水肿,小便不利,脚气,脾虚泄泻,湿痹拘挛,肺痈,肠痈等症。现代研究认为,薏苡仁具有抗肿瘤、免疫调节、降血糖血钙、降压、降脂减肥、抗疟原虫、抗病毒的功效。 In the study of traditional Chinese medicine, coix seed is used to treat edema, dysuria, beriberi, spleen deficiency and diarrhea, damp arthralgia, lung abscess, intestinal abscess and other diseases. Modern studies believe that coix seed has the effects of anti-tumor, immune regulation, lowering blood sugar and blood calcium, lowering blood pressure, lowering fat and losing weight, anti-malarial, and anti-virus. the
近年来公开文献报道了一些薏苡仁化学成分及药理作用的研究内容,例如:温晓蓉在《辽宁中医药大学学报》发表了“薏苡仁化学成分及抗肿瘤活性研究进 展”的文章,本文对薏苡仁的化学成分和药理研究进展进行了综述,包括该中药的主要成分如脂肪酸及酯、甾醇类、三萜类、生物碱类、多糖类化合物,以及有关抗病毒、免疫调节、抑制肿瘤血管生成、抗炎镇痛镇静作用的研究。 In recent years, published literature has reported some research contents on the chemical constituents and pharmacological effects of coix seed. The chemical composition and pharmacological research progress of Jennifer were reviewed, including the main components of the traditional Chinese medicine such as fatty acids and esters, sterols, triterpenoids, alkaloids, polysaccharides, and related antiviral, immune regulation, and tumor vascular inhibition. Generative, anti-inflammatory, analgesic and sedative effects. the
刘津,唐安洲,康敏等在《广西医学》发表了“薏苡仁提取物对鼻咽癌细胞作用的研究”的文章,研究薏苡仁提取物对鼻咽癌细胞株CNE1、CNE2、TWO3和C666-1细胞体外培养情况下的抑制作用。在倒置显微镜下观察其作用于鼻咽癌细胞后细胞形态学的改变。运用MTT法检测药物提取物及含药血清抑制细胞增殖的情况。结果证明薏苡仁可抑制CNE1、CNE2、TWO3和C666-1细胞的增殖,其作用具有时间和浓度依赖性。结论 薏苡仁提取物在体外实验中具有抗鼻咽癌细胞增殖的作用。 Liu Jin, Tang Anzhou, Kang Min, etc. published the article "Research on the Effect of Coix Seed Extract on Nasopharyngeal Cancer Cells" in "Guangxi Medicine", studying the effect of Coix Seed Extract on nasopharyngeal cancer cell lines CNE1, CNE2, TWO3 and C666- 1 Inhibitory effect of cells cultured in vitro. Observe the cell morphology changes after it acts on nasopharyngeal carcinoma cells under an inverted microscope. MTT method was used to detect the inhibitory effect of drug extracts and drug-containing serum on cell proliferation. The results proved that coix seed could inhibit the proliferation of CNE1, CNE2, TWO3 and C666-1 cells, and its effect was time- and concentration-dependent. Conclusion Coix seed extract has anti-proliferation effect on nasopharyngeal carcinoma cells in vitro. the
发明内容Contents of the invention
本发明的目的,是确定传统中药薏苡仁的药理作用——抗肿瘤(抗癌)作用,从薏苡仁中提取出抗肿瘤有效化学物质组分和提取方法,并用这些有效化学物质组分作为制备抗肿瘤(抗癌)作用药物的原料,从而更好的利用我国中草药资源,丰富中草药治疗疾病的领域。 The purpose of the present invention is to determine the pharmacological action of the traditional Chinese medicine coix seed - anti-tumor (anti-cancer) effect, to extract anti-tumor effective chemical components and extraction methods from coix seed, and to use these effective chemical components as a preparation Raw materials of anti-tumor (anti-cancer) drugs, so as to make better use of Chinese herbal medicine resources in China and enrich the field of Chinese herbal medicine for treating diseases. the
本发明人通过对薏苡仁药材的提取物进行研究,在体内外的抗癌试验研究表明其提取物有良好的抗肿瘤作用。 The present inventor has conducted research on the extract of the Coix seed medicinal material, and the in vivo and in vitro anticancer test studies have shown that the extract has a good antitumor effect. the
采用的技术方案是: The technical solution adopted is:
一种薏苡仁抗癌中药,其特征是为从薏苡仁中提取的具有抗肿瘤(抗癌)作用的化学物质组分。所述具有抗肿瘤作用的化学物质组分主要有: An anticancer traditional Chinese medicine of coix seed is characterized in that it is a chemical substance component with antitumor (anticancer) effect extracted from coix seed. The chemical substance components with anti-tumor effect mainly include:
1、三亚油酸甘油酯,分子式:C57H98O6,分子量:878.7{在液谱图中保留时间(min)为:9.721} 1. Glyceryl trilinoleate, molecular formula: C 57 H 98 O 6 , molecular weight: 878.7 {retention time (min) in the liquid chromatogram: 9.721}
2、二亚油酸油酸甘油酯,分子式:C57H100O6,分子量:880.8{在液谱图中保留时间(min)为:11.679} 2. Dilinoleic acid glyceryl oleate, molecular formula: C 57 H 100 O 6 , molecular weight: 880.8 {retention time (min) in the liquid chromatogram: 11.679}
3、棕榈酸二亚油酸甘油酯,分子式:C55H98O6,分子量:854.7{在液谱图中保留时间(min)为:12.228} 3. Glyceryl palmitate, molecular formula: C 55 H 98 O 6 , molecular weight: 854.7 {retention time (min) in the liquid chromatogram: 12.228}
4、亚油酸二油酸甘油酯,分子式:C57H102O6,分子量:882.8{在液谱图中保留时间(min)为:14.188} 4. Glyceryl linoleate, molecular formula: C 57 H 102 O 6 , molecular weight: 882.8 {retention time (min) in the liquid chromatogram: 14.188}
5、棕榈酸亚油酸油酸甘油酯,分子式:C55H100O6,分子量:856.8{在液谱图中保留时间(min)为:14.858} 5. Palmitic acid linoleic acid glyceryl oleate, molecular formula: C 55 H 100 O 6 , molecular weight: 856.8 {retention time (min) in the liquid chromatogram: 14.858}
6、二棕榈酸亚油酸甘油酯,分子式:C53H98O6,分子量:830.7{在液谱图中保留时间(min)为:15.584} 6. Dipalmitic linoleic acid glyceride, molecular formula: C 53 H 98 O 6 , molecular weight: 830.7 {retention time (min) in the liquid chromatogram: 15.584}
7、三油酸甘油酯,分子式:C57H104 O6,分子量:884.8{在液谱图中保留时间(min)为:17.370} 7. Glyceryl trioleate, molecular formula: C 57 H 104 O 6 , molecular weight: 884.8 {retention time (min) in the liquid chromatogram: 17.370}
8、棕榈酸二油酸甘油酯,分子式:C55H102 O6,分子量:858.8{在液谱图中保留时间(min)为:18.327} 8. Glyceryl palmitate, molecular formula: C 55 H 102 O 6 , molecular weight: 858.8 {retention time (min) in the liquid chromatogram: 18.327}
9、二棕榈酸油酸甘油酯,分子式:C53H100O6,分子量:832.8{在液谱图中保留时间(min)为:19.317} 9. Dipalmitic acid glyceryl oleate, molecular formula: C 53 H 100 O 6 , molecular weight: 832.8 {retention time (min) in the liquid chromatogram: 19.317}
10、二油酸硬脂酸甘油酯,分子式:C57H106O6,分子量:886.8{在液谱图中保留时间(min)为:22.140} 10. Glyceryl stearate dioleate, molecular formula: C 57 H 106 O 6 , molecular weight: 886.8 {retention time (min) in the liquid chromatogram: 22.140}
(见附图1) (See Attachment 1)
所述具有抗肿瘤作用的化学组分,在液相谱图色谱条件下:色谱柱为迪马C18 柱(4.6mm×250mm,5μm),流动相为乙腈-二氯甲烷(60∶40);流速:1mL/min;柱温:25℃;ELSD参数:漂移管温度35℃。 The chemical components with anti-tumor effect, under the liquid phase chromatographic conditions: the chromatographic column is a Dima C18 column (4.6mm × 250mm, 5 μm), and the mobile phase is acetonitrile-dichloromethane (60:40); Flow rate: 1mL/min; column temperature: 25°C; ELSD parameters: drift tube temperature 35°C. the
从薏苡仁中提取的有效化学物质组做成以下制剂或剂型:口服给药制剂:口服液、片剂、胶囊、含片、丸剂;注射给药制剂:注射剂;喷雾给药制剂。 The effective chemical substance group extracted from coix seed is made into the following preparations or dosage forms: oral administration preparations: oral liquid, tablets, capsules, buccal tablets, pills; injection administration preparations: injections; spray administration preparations. the
从薏苡仁中提取的具有抗癌作用的有效化学物质组分经实验证明在体内外均有抑制癌细胞增长作用,可应用于癌症的治疗。 The effective anti-cancer components extracted from coix seed have been proved by experiments to inhibit the growth of cancer cells both in vivo and in vitro, and can be applied to the treatment of cancer. the
具有抗癌作用的有效化学物质组分的提取方法,是将薏苡仁粗粉加适量乙酸乙酯回流提取3~4次,合并提取液,过滤,回收溶剂,减压干燥至无溶剂,即得薏苡仁有效物质组。 The method for extracting effective chemical components with anti-cancer effect is to add an appropriate amount of ethyl acetate to the coix seed coarse powder and reflux extraction for 3 to 4 times, combine the extracts, filter, recover the solvent, and dry under reduced pressure until no solvent is obtained. Coix Seed Effective Substance Group. the
本发明的优点在于:提取工艺简单、能制成多种剂型,具有较好的抗癌作用。 The invention has the advantages of simple extraction process, can be made into various dosage forms, and has good anticancer effect. the
附图说明Description of drawings
图1是从薏苡仁中提取具有抗肿瘤(抗癌)作用的有效化学组分的液相图谱。 Figure 1 is a liquid chromatogram of effective chemical components extracted from Coix Seed that have anti-tumor (anti-cancer) effects. the
图2是10%含药血清对人肝癌细胞HepG2的抑制作用示图。 Fig. 2 is a graph showing the inhibitory effect of 10% drug-containing serum on human liver cancer cell HepG2. the
图3是10%含药血清对人肝癌细胞SMMC-7721抑制作用示图。 Fig. 3 is a graph showing the inhibitory effect of 10% drug-containing serum on human liver cancer cell SMMC-7721. the
图2和图3中标号 为:阳性对照 Numbers in Figure 2 and Figure 3 For: positive control
为:高剂量 For: high dose
为:中剂量 For: medium dose
为:低剂量 For: low dose
具体实施方式Detailed ways
薏苡仁有效物质组分的提取: Extraction of effective components of coix seed:
提取前的处理:先将薏苡仁药材粉碎,过20目筛。 Pre-extraction treatment: crush the coix seed medicinal material first, and pass through a 20-mesh sieve. the
提取方法:加3倍量乙酸乙酯,70℃回流提取3次,合并提取液,过滤,回收溶剂,减压干燥至无溶剂,即得薏苡仁有效物质组分。 Extraction method: add 3 times the amount of ethyl acetate, reflux extraction at 70°C for 3 times, combine the extracts, filter, recover the solvent, dry under reduced pressure until there is no solvent, and obtain the effective components of coix seed. the
薏苡仁有效物质组的药理研究 Pharmacological study on the effective substance group of coix seed
对接种H22肝癌实体瘤的小鼠灌胃薏苡仁提取物,测定其抑制作用。 Mice inoculated with H22 liver cancer solid tumor were gavaged with coix seed extract, and its inhibitory effect was determined. the
体外试验,采用MTT法结合血清药理学方法,测定含薏苡仁提取物的小鼠血清对人肝癌细胞株HepG2、SMMC-7721的生长抑制情况,为薏苡仁提取物抗肿瘤(抗癌)作用的下一步研究奠定基础。 In vitro experiments, MTT method combined with serum pharmacology methods were used to determine the growth inhibition of mouse serum containing Coix seed extract on human liver cancer cell lines HepG2 and SMMC-7721, which is the proof of the anti-tumor (anti-cancer) effect of Coix seed extract. Foundation for further research. the
结论 in conclusion
在体内外实验中,薏苡仁有效物质组对肿瘤细胞的生长有明显的抑制作用。 In the in vivo and in vitro experiments, the effective substance group of coix seed has obvious inhibitory effect on the growth of tumor cells. the
抗肝癌药物的制备 Preparation of anti-liver cancer drugs
薏苡仁中具有抗癌作用的有效化学物质组可以制备成抗肝癌的药物,例如, 可根据需要,制备成不同的剂型:口服给药制剂,如口服液、片剂、胶囊、含片、丸剂;注射给药制剂,如注射剂;喷雾给药制剂等的抗癌试验中,其有良好的抗肝癌效果。 The effective chemical substance group with anti-cancer effect in coix seed can be prepared into anti-liver cancer drugs, for example, can be prepared into different dosage forms according to needs: oral administration preparations, such as oral liquid, tablet, capsule, buccal tablet, pill ; Injection preparations, such as injections; in the anti-cancer tests of spray preparations, etc., it has a good anti-liver cancer effect. the
1.材料与方法 1. Materials and methods
1.1材料 人肝癌细胞株HepG2、SMMC-7721,小鼠肝癌H22细胞株均购自上海复蒙生物有限公司,本实验室传代保存。清洁级昆明种小鼠,体重(18-20g),雌性,(购于大连医科大学实验动物中心,合格证号为:SCXX(辽)2008-0002)。薏苡仁购自市面超市。 1.1 Materials Human liver cancer cell lines HepG2 and SMMC-7721, and mouse liver cancer H22 cell lines were purchased from Shanghai Fumeng Biological Co., Ltd. and preserved in our laboratory. Clean-grade Kunming mice, body weight (18-20g), female (purchased from the Experimental Animal Center of Dalian Medical University, certificate number: SCXX (Liao) 2008-0002). Coix seed was purchased from a supermarket. the
1.2试剂及仪器 DMEM培养基、胰蛋白酶、四甲基偶氮唑盐(MTT)均由美国GIBCO公司出品;二甲基亚砜(DMSO):北京索莱宝科技有限公司;小牛血清(NBCS):杭州四季青生物工程材料有限公司;青霉素:哈药集团制药总厂批号:A081100207;链霉素:大连美罗大药厂批号:65081216;环磷酰胺:江苏恒瑞医药股分有限公司批号:09040721 1.2 Reagents and instruments DMEM medium, trypsin, and tetramethylazolium salt (MTT) were all produced by GIBCO in the United States; dimethyl sulfoxide (DMSO): Beijing Solaibao Technology Co., Ltd.; calf serum (NBCS ): Hangzhou Sijiqing Bioengineering Materials Co., Ltd.; Penicillin: Harbin Pharmaceutical Group Pharmaceutical Factory Batch No.: A081100207; Streptomycin: Dalian Merro Pharmaceutical Factory Batch No.: 65081216; Cyclophosphamide: Jiangsu Hengrui Pharmaceutical Co., Ltd. Batch No. : 09040721
ACCULAB ALC-11C.4型电子天平:德国赛多利斯集团;NUAIRETM US AUTOFLOW型CO2培养箱:德国NUAIRE公司;BCN-1360B型生物洁净工作台:北京东联哈尔仪器制造有限公司;AE31型倒置相差显微镜:Motic公司;SUNRISE酶标仪:瑞士TECAN公司;Milli-Q超纯水处理装置:美国Millipore公司;不锈钢正压滤器(500mL):海宁市亚泰制药机械有限公司;96孔无菌培养板:美国Costar公司;手提式压力蒸汽消毒器:丹东市日用五金厂;血球计数板:上海求精生化仪器厂 ACCULAB ALC-11C.4 electronic balance: Sartorius Group, Germany; NUAIRETM US AUTOFLOW CO 2 incubator: NUAIRE, Germany; BCN-1360B biological clean bench: Beijing Donglian Haer Instrument Manufacturing Co., Ltd.; AE31 Inverted phase contrast microscope: Motic; SUNRISE microplate reader: TECAN, Switzerland; Milli-Q ultrapure water treatment device: Millipore, USA; stainless steel positive pressure filter (500mL): Haining Yatai Pharmaceutical Machinery Co., Ltd.; 96 wells sterile Culture plate: American Costar Company; portable pressure steam sterilizer: Dandong Daily Hardware Factory; blood counting plate: Shanghai Qiujing Biochemical Instrument Factory
1.3 实验方法 1.3 Experimental method
1.3.1 药物的制备 薏苡仁药材粗粉,乙酸乙酯回流提取,回收溶剂。 1.3.1 Preparation of drug Coix seed coarse powder, reflux extraction with ethyl acetate, recovery of solvent. the
1.3.2 动物分组及给药剂量 将小鼠随机分6组,每组10只。分别为空白对照组;阴性对照组,灌胃生理盐水,每日0.2ml;环磷酰胺对照组(CTX),剂量20mg·kg-1·d-1;薏苡仁提取物大、中、小剂量组分别为3,1,0.3g·kg-1·d-1。 1.3.2 Grouping of animals and dosage The mice were randomly divided into 6 groups, 10 in each group. They were blank control group; negative control group, intragastric administration of normal saline, 0.2ml per day; cyclophosphamide control group (CTX), dose 20mg·kg -1 ·d -1 ; large, medium and small doses of coix seed extract The groups are 3, 1, and 0.3 g·kg -1 ·d -1 , respectively.
1.3.3 给药方法及样品制备 各组按常规方法接种H22瘤株,瘤细胞(冰浴)2×107/mL,每鼠于右前腋下接种0.2mL,接种次日开始给药,每日1次,用药10天。各组小鼠均于末次给药后1h进行以下试验:称重后,摘眼球取血,滴入离心管内,全血于37℃温孵30min后,3500r·min-1离心10min,吸取上部血清,同组血清合并,0.45um、0.22um微孔滤膜依次过滤除菌,置-80℃冰箱保存备用。颈椎脱臼处死,完整剥离瘤块,精密电子天平称重并记录,计算肿瘤抑制率。 1.3.3 Administration method and sample preparation Each group was inoculated with H22 tumor strain according to conventional methods, tumor cells (ice bath) 2×10 7 /mL, each mouse was inoculated with 0.2mL in the right anterior armpit, and the administration was started on the next day after inoculation. 1 time a day, 10 days of medication. The mice in each group were subjected to the
肿瘤抑制率(%)=[(对照组平均瘤重-给药组平均瘤重)/对照组平均瘤重]×100% Tumor inhibition rate (%)=[(average tumor weight in the control group-average tumor weight in the administration group)/average tumor weight in the control group]×100%
1.3.4 MTT(噻唑兰)试验 人肝癌细胞HepG2、SMMC-7721接种在含10%灭活的新生小牛血清的DMEM培养液中,置37℃,5%CO2的孵箱中培养,每2~3d用0.25%胰酶消化传代。传2~3代后,取处于对数生长期、生长状态良好的细胞1瓶,经PBS清洗,用0.25%的胰酶消化,待细胞趋于变圆用培养液冲洗吹打细胞,制成细胞悬液。用血球计数板计数,加培养液稀释至浓度为5×104个/mL,接种于96孔培养板,每孔100uL。培养24h后,加入含不同实验组不同浓度血清的培养液,每组设5个复孔。培养箱中连续培养24h、48h、72h、96h,分别加入20uL的MTT(5mg/mL)溶液,继续培养4h后吸去上清液,每孔加入二甲基亚枫150uL,振荡,至溴代噻唑蓝完全溶解,在492nm波长处用酶标仪测其吸光度(OD),测定时需减去空白对照的吸光度(OD)。 1.3.4 MTT (thiazolium) test Human liver cancer cells HepG2 and SMMC-7721 were inoculated in DMEM culture medium containing 10% inactivated newborn calf serum, and cultured in an incubator at 37°C and 5% CO 2 . Digest and passage with 0.25% trypsin on 2-3 days. After 2 to 3 passages, take a bottle of cells in logarithmic growth phase and in good growth state, wash with PBS, digest with 0.25% trypsin, and when the cells tend to become round, wash and blow the cells with culture medium to make cells Suspension. Count with a hemocytometer, add culture medium to dilute to a concentration of 5×10 4 cells/mL, inoculate in a 96-well culture plate, 100 uL per well. After culturing for 24 hours, culture medium containing different concentrations of serum from different experimental groups was added, and 5 replicate wells were set up in each group. Cultivate continuously in the incubator for 24h, 48h, 72h, and 96h, add 20uL of MTT (5mg/mL) solution respectively, continue to cultivate for 4h, suck off the supernatant, add 150uL of dimethyl sulfoxide to each well, shake until bromo The thiazolyl blue was completely dissolved, and its absorbance (OD) was measured with a microplate reader at a wavelength of 492nm, and the absorbance (OD) of the blank control was subtracted during the measurement.
细胞生长抑制率(IC%)=[(对照组OD-给药组OD)/对照组OD]×100% Cell growth inhibition rate (IC%)=[(control group OD-administration group OD)/control group OD]×100%
1.3.5 统计学处理 各项参数均以 表示,数据用SPSS15.0软件分析。 1.3.5 Statistical processing Indicates that the data were analyzed with SPSS15.0 software.
2结果 2 result
2.1 薏苡仁提取物对小鼠H22肝癌实体瘤的抑制作用 各剂量抑制率均高于30%,具有较明显的抑制作用,抑瘤率与给药剂量呈线性关系,与阴性对照组比较平均瘤重具有显著性差异(P<0.05),与环磷酰胺对照组比较无显著性差异(P>0.05)(见表1)。 2.1 Inhibitory effect of coix seed extract on mouse H22 liver cancer solid tumor The inhibition rate of each dose is higher than 30%, which has obvious inhibitory effect. The tumor inhibition rate has a linear relationship with the administered dose. Compared with the negative control group, the average There was a significant difference in weight (P<0.05), but no significant difference compared with the cyclophosphamide control group (P>0.05) (see Table 1). the
2.2 含药血清对人肿瘤细胞株的体外抑制作用 各作用时间CTX血清,薏苡仁大、中、小剂量组含药血清的OD值与空白血清的OD值相比,差异显著(P<0.05)(见表2)。 2.2 The in vitro inhibitory effect of drug-containing serum on human tumor cell lines The OD values of drug-containing serum in CTX serum, Coix seed large, medium and small dose groups were significantly different from those of blank serum at each time of action (P<0.05) (See Table 2). the
表1 薏苡仁提取物对小鼠H22肝癌实体瘤的抑制作用 Table 1 Inhibitory effect of coix seed extract on H22 liver cancer solid tumor in mice
注:与对照组比较*P<0.05 Note: Compared with the control group *P<0.05
表2 10%含药血清对人肿瘤细胞株的体外抑制作用 Table 2 In vitro inhibitory effect of 10% drug-containing serum on human tumor cell lines
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010237432 CN101940738A (en) | 2010-07-27 | 2010-07-27 | Coix seed anticancer Chinese medicament and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010237432 CN101940738A (en) | 2010-07-27 | 2010-07-27 | Coix seed anticancer Chinese medicament and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101940738A true CN101940738A (en) | 2011-01-12 |
Family
ID=43433068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010237432 Pending CN101940738A (en) | 2010-07-27 | 2010-07-27 | Coix seed anticancer Chinese medicament and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101940738A (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104173824A (en) * | 2014-07-18 | 2014-12-03 | 浙江康莱特集团有限公司 | Coix seed oil containing 8 triglycerides as well as preparation and application of coix seed oil |
CN105254498A (en) * | 2014-07-18 | 2016-01-20 | 浙江康莱特集团有限公司 | 1,3-oleic acid-2-linoleic acid glyceride, preparation, preparation method and applications thereof |
WO2016008438A1 (en) * | 2014-07-18 | 2016-01-21 | 浙江康莱特集团有限公司 | Pharmaceutical composition comprising 8 triglycerides, formulation and application thereof |
WO2016008441A1 (en) * | 2014-07-18 | 2016-01-21 | 浙江康莱特集团有限公司 | Pharmaceutical compound comprising 13 glycerides, formulation and application thereof |
WO2016008437A1 (en) * | 2014-07-18 | 2016-01-21 | 浙江康莱特集团有限公司 | Glyceryl 1-palmitate-2-linoleate-3-oleate compound, formulation, and preparation method and application thereof |
CN105267776A (en) * | 2014-07-18 | 2016-01-27 | 浙江康莱特集团有限公司 | Coix seed oil containing 13 glycerides, and preparation and application thereof |
JP2017521497A (en) * | 2014-07-18 | 2017-08-03 | ゼンジアン カングライト グループ シーオー.、エルティーディー. | Yokuinin oil containing 16 kinds of glycerides, formulation and application |
JP2017522441A (en) * | 2014-07-18 | 2017-08-10 | ゼンジアン カングライト グループ シーオー.、エルティーディー. | Yokuinin oil containing 11 kinds of triglycerides, formulation and application |
CN109234016A (en) * | 2018-10-19 | 2019-01-18 | 福建农林大学 | A kind of tea tree ethereal oil preparation method with inhibition cancer cell multiplication effect |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1647797A (en) * | 2004-09-27 | 2005-08-03 | 北京八木医药技术发展有限公司 | Formula of submicro emulsion of norcantharidine injection and preparing process |
-
2010
- 2010-07-27 CN CN 201010237432 patent/CN101940738A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1647797A (en) * | 2004-09-27 | 2005-08-03 | 北京八木医药技术发展有限公司 | Formula of submicro emulsion of norcantharidine injection and preparing process |
Non-Patent Citations (1)
Title |
---|
《中国中药杂志》 20050930 向智敏等 HPLC-MS分析薏苡仁油中的甘油三酯成分 第1436-1438页 1-3 第30卷, 第18期 2 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105287479A (en) * | 2014-07-18 | 2016-02-03 | 浙江康莱特集团有限公司 | Pharmaceutical composition containing 8 kinds of triglycerides, preparation and application thereof |
CN104173824B (en) * | 2014-07-18 | 2017-02-15 | 浙江康莱特集团有限公司 | Coix seed oil containing 8 triglycerides as well as preparation and application of coix seed oil |
WO2016008436A1 (en) * | 2014-07-18 | 2016-01-21 | 浙江康莱特集团有限公司 | Glyceryl 1, 3-dioleate-2-linoleate compound, formulation, and preparation method and application thereof |
WO2016008438A1 (en) * | 2014-07-18 | 2016-01-21 | 浙江康莱特集团有限公司 | Pharmaceutical composition comprising 8 triglycerides, formulation and application thereof |
WO2016008441A1 (en) * | 2014-07-18 | 2016-01-21 | 浙江康莱特集团有限公司 | Pharmaceutical compound comprising 13 glycerides, formulation and application thereof |
WO2016008437A1 (en) * | 2014-07-18 | 2016-01-21 | 浙江康莱特集团有限公司 | Glyceryl 1-palmitate-2-linoleate-3-oleate compound, formulation, and preparation method and application thereof |
CN105267776A (en) * | 2014-07-18 | 2016-01-27 | 浙江康莱特集团有限公司 | Coix seed oil containing 13 glycerides, and preparation and application thereof |
CN105267197A (en) * | 2014-07-18 | 2016-01-27 | 浙江康莱特集团有限公司 | Pharmaceutical composition containing 13 glycerides, and preparation and application thereof |
CN105254498A (en) * | 2014-07-18 | 2016-01-20 | 浙江康莱特集团有限公司 | 1,3-oleic acid-2-linoleic acid glyceride, preparation, preparation method and applications thereof |
CN104173824A (en) * | 2014-07-18 | 2014-12-03 | 浙江康莱特集团有限公司 | Coix seed oil containing 8 triglycerides as well as preparation and application of coix seed oil |
CN105294438A (en) * | 2014-07-18 | 2016-02-03 | 浙江康莱特集团有限公司 | Compound, namely, 1-palmitic acid-2-linoleic acid-3-olein, preparation, preparation method and application |
JP2017521497A (en) * | 2014-07-18 | 2017-08-03 | ゼンジアン カングライト グループ シーオー.、エルティーディー. | Yokuinin oil containing 16 kinds of glycerides, formulation and application |
JP2017522441A (en) * | 2014-07-18 | 2017-08-10 | ゼンジアン カングライト グループ シーオー.、エルティーディー. | Yokuinin oil containing 11 kinds of triglycerides, formulation and application |
JP2017524047A (en) * | 2014-07-18 | 2017-08-24 | ゼンジアン カングライト グループ シーオー.、エルティーディー. | Yokuinin oil containing 13 kinds of glycerides, formulation and application |
JP2017524697A (en) * | 2014-07-18 | 2017-08-31 | ゼンジアン カングライト グループ シーオー.、エルティーディー. | Pharmaceutical composition comprising 13 glycerides, formulation and application thereof |
AU2015291530B2 (en) * | 2014-07-18 | 2018-03-15 | Zhejiang Kanglaite Group Co., Ltd. | Pharmaceutical composition containing 13 glycerides, and preparations and use thereof |
EA033077B1 (en) * | 2014-07-18 | 2019-08-30 | Чжэцзян Канлайтэ Груп Ко., Лтд. | Pharmaceutical composition containing 13 triglycerides, and preparations and use thereof |
CN109234016A (en) * | 2018-10-19 | 2019-01-18 | 福建农林大学 | A kind of tea tree ethereal oil preparation method with inhibition cancer cell multiplication effect |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101940738A (en) | Coix seed anticancer Chinese medicament and preparation method thereof | |
JP5380420B2 (en) | Composition for preventing or treating degenerative cranial nerve disease containing longan meat extract or mixed extract containing the same | |
CN104435034B (en) | A kind of arasaponin and preparation method thereof | |
CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
CN102247391B (en) | Application of panax japonicus saponin V to reduction of blood fat | |
KR20210021226A (en) | Composition for preventing or treating lipid metabolism diseases comprising extract of salvia miltiorrhiza or paeonia lactiflora | |
CN102512485A (en) | Traditional Chinese medicine for treating acute hepatitis, chronic hepatitis and hepatic fibrosis | |
CN109045035A (en) | Application of 7- (2,2- dimethyl -3- crotonoyl the amido)-octahydro benzene quinoline acetic acid esters in preparation treatment liver disease drug | |
CN103766901A (en) | Application of andrographolide C to preparation of weight-losing food or medicine | |
Xu et al. | Study on anti-tumor effect of total glycosides from Radix paeoniae rubra in S180 tumor-bearing mice | |
CN103610675A (en) | Application of jateorhizine in pharmacy | |
Chen et al. | Study on the effect of polysaccharides from Solanum nigrum Linne on cellular immune function in tumour-bearing mice | |
CN117770442A (en) | Camellia oil-based liver protection composition and application thereof | |
CN113730464A (en) | New application of rhizoma coptidis pill, extract and pharmaceutical composition thereof and rhizoma coptidis pill product | |
CN102247413A (en) | Hypolipidemic effects of radix dipsaci total saponin and akebia stem saponin D | |
RU2519769C1 (en) | Agent possessing antineoplastic and immunomodulatory action | |
CN106632716B (en) | Chinese pholidota pseudobulb or herb polysaccharide is preparing the application in hepatic | |
CN107485615A (en) | Purposes of the Ligustrum robust glycosides C and combinations thereof in treatment hyperlipidemia and slimming medicine is prepared | |
CN113679759A (en) | Application of a safflower seed extract in the preparation of a drug for preventing or treating non-alcoholic fatty liver disease | |
CN101664423A (en) | Hypoglycemic active part of osmanthus fragrans, preparation method and application thereof | |
Guan et al. | Study on anti-tumor effect of Solanum lyratum Thunb. extract in S180 tumor-bearing mice | |
CN113559144A (en) | Application of glycyrrhiza glabra crude extract in treating non-alcoholic fatty liver disease | |
CN113616670A (en) | Application of red ginseng pectin-like polysaccharide in preparation of lipid-lowering drugs or health-care products | |
CN111544440A (en) | Application of diosmin and composition in preparation of anti-obesity product | |
CN110840950A (en) | Application of Russian tea and/or Russian tea extract in preparation of medicines for preventing and treating non-alcoholic liver disease and/or non-alcoholic liver injury |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Open date: 20110112 |